氯吡格雷联合速效救心丸治疗急性冠状动脉综合征的临床效果观察

摘要

Objective To observe the clinical effect of clopidogrel combination with Suxiaojiuxinwan treatment of acute coronary,in order to explore the investigate the clinical applicability. Methods 88 patients with acute coronary syn-dromes treated in our hospital from March 2012 to December 2013 were selected,they were simple randomly divided into experimental group in 45 cases and the control group in 43 cases,the control group was given clopidogrel treat-ment,the experimental group was given clopidogrel combination with Suxiaojiuxinwan treatment.The treatment effects and the improvement of blood rheology of two groups were observed. Results The electrocardiogram (ECG) treatment ef-fective rate in experimental group was 93.33%,the control group was 76.74%,the difference was statistically significant between the two groups (字2=4.8063,P=0.0284).The treatment effective rate in experimental group was 95.56%,the con-trol group was 81.40%,the difference was statistically significant between the two groups (χ²=4.3773,P=0.0364).Patients with no obvious bleeding occurred after taking the drug adverse reactions,the experimental group patients in the im-provement of the whole blood viscosity and plasma viscosity were superior to control group patients,the differences were statistically significant (P<0.05),the patients with platelet adhesion rate in experimental group and the control group was almost,there was no statistically significant difference (P>0.05). Conclusion Clopidogrel combination with Suxiaojiuxin-wan treatment of acute coronary syndromes is more effective,safe,and suitable for clinical application.%目的：观察氯吡格雷联合速效救心丸治疗急性冠状动脉综合征的临床效果，以探讨其临床适用性。方法选择2012年3月~2013年12月于本院就诊的88例急性冠状动脉综合征患者，简单随机分为试验组45例和对照组43例，对照组给予氯吡格雷治疗，试验组则采用氯吡格雷联合速效救心丸治疗。观察两组患者的治疗效果及血液流变学的改善情况。结果试验组患者的心电图治疗有效率为93.33%，对照组为76.74%，两组比较差异有统计学意义(χ²=4.8063，P=0.0284)。试验组患者的治疗有效率为95.56%，对照组为81.40%，两组比较差异有统计学意义(字2=4.3773，P=0.0364)。患者服药后均未出现明显出血等不良反应；试验组患者的全血黏度和血浆黏度的改善情况均优于对照组，差异均有统计学意义(P<0.05)，试验组患者的血小板黏附率与对照组相当，差异无统计学意义(P>0.05)。结论氯吡格雷联合速效救心丸治疗急性冠状动脉综合征更有效、安全，适合临床推广应用。